Nexalin Technology Reports Results Of Clinical Study Supporting The Therapeutic Benefits Of Its Gen-2, 15 Milliamp Neurostimulation Device In Treating Migraine Headaches And Related Symptoms
Portfolio Pulse from Benzinga Newsdesk
Nexalin Technology has reported positive results from a clinical study of its Gen-2, 15 milliamp neurostimulation device for treating migraine headaches and related symptoms. The study supports the therapeutic benefits of the device.
August 07, 2023 | 12:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nexalin Technology's positive clinical study results could boost the company's reputation and sales, potentially leading to a positive impact on its stock price.
Positive clinical study results often lead to increased sales as they boost the reputation of the company and its products. This could lead to increased revenues for Nexalin Technology, which could positively impact its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100